(Total Views: 315)
Posted On: 04/20/2020 7:08:31 AM
Post# of 11803
Pal, that was prior to the EUA guideline adoption and then modification. It’s apparent you will go to any length to discredit the company and its leaders. Your narrative is biased, flawed and just wrong.
We get your position, your lack of credibility and your detesting of DECN. Haven’t we been subjected to enough BS from you?
“In Vitro Diagnostics EUAs
On the basis of the February 4, 2020 HHS EUA determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of the novel coronavirus (2019-nCoV) subject to the terms of any authorization issued under section 564(a) of the Act.
On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to this public health emergency. This guidance was updated on March 16, 2020.“
We get your position, your lack of credibility and your detesting of DECN. Haven’t we been subjected to enough BS from you?
“In Vitro Diagnostics EUAs
On the basis of the February 4, 2020 HHS EUA determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of the novel coronavirus (2019-nCoV) subject to the terms of any authorization issued under section 564(a) of the Act.
On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to this public health emergency. This guidance was updated on March 16, 2020.“
(1)
(1)
